Myocardial Infarction - Pipeline Insight, 2025
Description
DelveInsight’s, “Myocardial Infarction - Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Myocardial Infarction: Overview
A myocardial infarction, commonly known as a heart attack, is the irreversible necrosis of heart muscle due to prolonged ischemia, usually caused by a blockage in the arteries that supply blood to the heart. If a healthcare provider doesn’t restore blood flow quickly, a heart attack can cause permanent heart damage and death. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of the coronary arteries. Treatment for a heart attack aims to restore blood flow to the affected heart muscle as soon as possible, and it can involve various methods, such as medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. Several key factors affect the risk of having a heart attack, including family history, high blood pressure, high cholesterol, and smoking.
The symptoms of a heart attack can vary, but common symptoms include chest pain, discomfort, pain or discomfort in the jaw, neck, or back, shortness of breath, and nausea. It's important to seek emergency medical help if you experience any of these symptoms. Early and rapid electrocardiogram (ECG) testing is essential for diagnosis, with ECG being about 95% to 97% specific to myocardial infarction.
Lifestyle changes such as controlling high-fat, cholesterol, and salt diet, reducing alcohol consumption and smoking, regular exercise, weight control, blood pressure monitoring, stress reduction, and keeping aspirin for chest pain are recommended for prevention and management of myocardial infarction. The immediate treatment of MI includes taking aspirin, nitroglycerin, and oxygen. To prevent heart attacks, it's important to take earlier action to lower risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, and drugs. The treatment of MI also includes the use of thrombolytic or clot-dissolving drugs, painkillers, and antihypertensive drugs to lower blood pressure and improve the heart's oxygen demand.
“Myocardial Infarction - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myocardial Infarction pipeline landscape is provided which includes the disease overview and Myocardial Infarction treatment guidelines. The assessment part of the report embraces, in depth Myocardial Infarction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myocardial Infarction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Myocardial Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myocardial Infarction Emerging Drugs
FDY 5301: Faraday Pharmaceuticals
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Currently, the drug is in Phase III stage of its clinical trial for the treatment AMI.
Glenzocimab: Acticor Biotech
Glenzocimab is a humanized monoclonal antibody fragment designed to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Currently, it is in Phase II stage of its clinical trial for the treatment of myocardial infarction.
BI765845: Boehringer Ingelheim
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myocardial infarction.
Further product details are provided in the report……..
Myocardial Infarction: Therapeutic Assessment
This segment of the report provides insights about the different Myocardial Infarction drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
Myocardial Infarction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myocardial Infarction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocardial Infarction drugs.
Myocardial Infarction Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Myocardial Infarction: Overview
A myocardial infarction, commonly known as a heart attack, is the irreversible necrosis of heart muscle due to prolonged ischemia, usually caused by a blockage in the arteries that supply blood to the heart. If a healthcare provider doesn’t restore blood flow quickly, a heart attack can cause permanent heart damage and death. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of the coronary arteries. Treatment for a heart attack aims to restore blood flow to the affected heart muscle as soon as possible, and it can involve various methods, such as medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. Several key factors affect the risk of having a heart attack, including family history, high blood pressure, high cholesterol, and smoking.
The symptoms of a heart attack can vary, but common symptoms include chest pain, discomfort, pain or discomfort in the jaw, neck, or back, shortness of breath, and nausea. It's important to seek emergency medical help if you experience any of these symptoms. Early and rapid electrocardiogram (ECG) testing is essential for diagnosis, with ECG being about 95% to 97% specific to myocardial infarction.
Lifestyle changes such as controlling high-fat, cholesterol, and salt diet, reducing alcohol consumption and smoking, regular exercise, weight control, blood pressure monitoring, stress reduction, and keeping aspirin for chest pain are recommended for prevention and management of myocardial infarction. The immediate treatment of MI includes taking aspirin, nitroglycerin, and oxygen. To prevent heart attacks, it's important to take earlier action to lower risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, and drugs. The treatment of MI also includes the use of thrombolytic or clot-dissolving drugs, painkillers, and antihypertensive drugs to lower blood pressure and improve the heart's oxygen demand.
“Myocardial Infarction - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myocardial Infarction pipeline landscape is provided which includes the disease overview and Myocardial Infarction treatment guidelines. The assessment part of the report embraces, in depth Myocardial Infarction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myocardial Infarction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial Infarction R&D. The therapies under development are focused on novel approaches to treat/improve Myocardial Infarction.
This segment of the Myocardial Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myocardial Infarction Emerging Drugs
FDY 5301: Faraday Pharmaceuticals
FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Currently, the drug is in Phase III stage of its clinical trial for the treatment AMI.
Glenzocimab: Acticor Biotech
Glenzocimab is a humanized monoclonal antibody fragment designed to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Currently, it is in Phase II stage of its clinical trial for the treatment of myocardial infarction.
BI765845: Boehringer Ingelheim
BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myocardial infarction.
Further product details are provided in the report……..
Myocardial Infarction: Therapeutic Assessment
This segment of the report provides insights about the different Myocardial Infarction drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Myocardial Infarction
Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Myocardial Infarction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myocardial Infarction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocardial Infarction drugs.
Myocardial Infarction Report Insights
- Myocardial Infarction Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myocardial Infarction drugs?
- How many Myocardial Infarction drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocardial Infarction?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myocardial Infarction therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myocardial Infarction and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novo Nordisk
- CeleCor Therapeutics
- Bayer
- Shanghai Zhongshan Hospital
- Takeda Pharmaceuticals
- Nexel
- Moleac Pte Ltd.
- LIB Therapeutics
- Windtree Therapeutics
- Faraday Pharmaceuticals
- CSL Behring
- Cardior Pharmaceuticals
- AstraZeneca
- R-Pharma
- Shilpa Biologicals
- Ziltivekimab
- RUC-4 Compound
- Rivaroxaban
- Pirfenidone
- Pioglitazone
- NP-011
- MLC1501
- Lerodalcibep
- Istaroxime
- FDY-5301
- CSL300
- CDR132L
- AZD3366
- RPH-104
- SBDM 05
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Myocardial Infarction : Overview
- Introduction
- Structure
- Function
- Mechanism of action
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Myocardial Infarction – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- FDY 5301: Faraday Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Glenzocimab: Acticor Biotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Mid Stage Products (Phase II)
- Preclinical Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Myocardial Infarction - Collaborations Assessment- Licensing / Partnering / Funding
- Myocardial Infarction - Unmet Needs
- Myocardial Infarction - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
